Research Education

美国的抗癌药物几乎完全由欧洲开发、测试和优化， 美国人美国药物开发的差异是长期存在的不平等的结果， 整个药物研发流程只有少数基础，翻译和临床科学家 拉丁裔/西班牙裔美国人或非洲裔美国人。不到2 - 5%的试验参与者是拉丁裔/西班牙裔- 美国人或非裔美国人然而，尽管缺乏数据，美国食品和药物管理局批准了新药， 美国药品监督管理局（FDA），随后规定为拉丁裔/西班牙裔美国人或非洲裔美国人 患者没有经过充分的检查。这是不可接受的，特别是在这个精准医学倡议的时代， (PMI)我们的药物目前是由我们的公民中的一部分人开发和优化的。 我们寻求通过加强加州大学与 滨江（UCR）和希望之城综合癌症中心（CoHCCC）。U54研究的目标 教育核心是UCR和CoHCCC合作开发研究基础设施和培训 培养下一代反映种族多样性的治疗学研究人员所必需的计划 位于南加州内陆。为此，UCR-CoHCCC研究教育核心将整合研究 经验，课程开发和推广教育活动，重点是：1）药物滥用的机会 发现，2）将基础科学发现转化为推动药物开发的资源，以及3） 生物学、伦理学和社会决定因素。目标1将开发研究途径以提高能力 药物开发和临床试验。目标2将开发课程，介绍UCR和CoH学生， 学院的方法和创新药物开发和健康科学的差距。（学生，PDF， 早期研究人员（ESI），建立教师）。目标3将1）暴露学生，PDF，ESI职业生涯 提供药物开发和临床试验的机会; 2）提供培训和能力建设。

Cancer drugs in the United States are almost exclusively developed by, tested in, and optimized for European- Americans. Disparities in U.S. drug development are the result of long-standing inequalities that occur throughout the entire drug discovery pipeline. Only a small number of basic, translational, and clinical scientists are Latino/Hispanic-American or African-American. Less than 2-5% of trial participants are Latino/Hispanic- American or African-American. Yet, in spite of a lack of data, new drugs are approved by the U.S. Food and Drug Administration (FDA), and subsequently prescribed for Latino/Hispanic-American or African-American patients, without sufficient testing. It is unacceptable, especially in this era of the Precision Medicine Initiative (PMI), that our drugs are currently developed by, and optimized for, only an exclusive segment of our citizens. We seek to shift this paradigm by strengthening the existing partnership between University of California at Riverside (UCR) and City of Hope Comprehensive Cancer Center (CoHCCC). The goal of our U54 Research Education Core is for UCR and CoHCCC to collaboratively develop the research infrastructure and training programs necessary to develop the next generation of therapeutics researchers that reflect the ethnic diversity of Inland Southern California. To this end, the UCR – CoHCCC Research Education Core will integrate research experiences, curriculum development, and outreach education activities that focus on 1) opportunities in drug discovery, 2) resources to translate basic science discovery to drive drug development, and 3) training in the biology, ethics, and social determinants of disparities. Aim 1 will develop research pathways to increase capacity in drug development and clinical trials. Aim 2 will develop courses to introduce both UCR and CoH students and faculty to methods and innovation in drug development and the health science of disparities. (students, PDF, early stage investigators (ESI), established faculty). Aim 3 will 1) expose students, PDF, ESI to career opportunities in drug development and clinical trials and 2) provide training and capacity building.